

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/17981 A1

(51) International Patent Classification⁷: A61L 15/46,
15/20, 15/26, 15/42, 15/48

(72) Inventors; and

(75) Inventors/Applicants (for US only): KLUGER, Ram
[IL/IL]; 82 Ha'erez Street, 42815 Pardesia (IL). BENITA,
Simon [IL/IL]; 33/3 Ha'arazim Street, 90805 Mevaseret
Zion (IL). STERN, Theodor [IL/IL]; P.O. Box 39103,
91390 Jerusalem (IL).

(21) International Application Number: PCT/IL01/00419

(74) Agent: REINHOLD COHN AND PARTNERS; P.O.
Box 4060, 61040 Tel Aviv (IL).

(22) International Filing Date: 11 May 2001 (11.05.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.

(25) Filing Language: English



(26) Publication Language: English

(30) Priority Data:
138183 31 August 2000 (31.08.2000) IL


(71) Applicants (for all designated States except US): ROTAM LTD. [IL/IL]; P.O. Box 3541, 38900 Caesarea (IL). VISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM [IL/IL]; P.O. Box 4279, 91042 Jerusalem (IL).

[Continued on next page]


(54) Title: pH REDUCING FORMULATION FOR A TAMPON



a



b



c

(57) Abstract: A formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5, comprising (a) 3-80 % by weight of a solid organic acid polymer; (b) 92-15 % by weight of a solid organic acid; and (c) 5-30 % of a wetting agent. Also disclosed is a delivery system for releasing an active agent comprising: (a) a deposition comprising the active agent; and (b) a polymeric support on which the deposition is deposited. The delivery system is especially useful in a catamenial tampon for insertion in a human vagina which comprises (a) an inner core comprising an absorbent material; (b) an outer layer comprising a liquid permeable material; and (c) the delivery system.

WO 02/17981 A1



(84) **Designated States (regional):** ARIPO patent (GII, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CE, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

pH REDUCING FORMULATION FOR A TAMPON

FIELD OF THE INVENTION

This invention relates to a pH-reducing formulation, an active agent delivery system and a tampon comprising the same.

BACKGROUND OF THE INVENTION

5 The normal, healthy human vagina is weakly acidic and has a pH of approximately 4.5. This acid condition of the vagina provides an effective barrier against the growth of pathogenic microorganisms normally associated with vaginal infection, because such microorganisms do not grow below a pH of about 5. If, however, the pH of the vagina becomes less acidic, i.e., higher than about 5,
10 pathogenic microorganisms tend to multiply.

A change in pH of the vagina from the normal of about 4.5 to 5 to a more alkaline pH may be brought about by various vaginal conditions and may occur at any time during the menstrual cycle. During menstruation, in particular, the vagina becomes less acidic due to the presence of menstrual fluid which has a pH of from
15 about 7 to 8. As a result, the protective barrier provided by the normal acidic condition of the vagina becomes less effective, thereby providing an environment favorable to the growth of the pathogenic microorganisms.

To overcome the reduction in acidity of the vagina and to re-establish the desired normal acidic condition, different formulations and techniques have been
20 developed. Such efforts have included the development of formulations such as solutions, jellies, powders, suppositories, and the like containing acidifying materials which are introduced into the vagina in their prepared form.

- 2 -

While the above-mentioned types of products have met with acceptance, they are subject to numerous disadvantages. The solutions, jellies, powders, and suppositories containing acidifying materials may be inconvenient to handle and apply and are not fully retained in the vagina and tend to escape. In addition, they 5 do not have capacity for absorbing vaginal fluid which may be present in the vagina, particularly during menstruation. Therefore, to use such products during menstruation, it is also necessary to use at the same time a catamenial tampon or similar article.

Other attempts to lower the pH have included physically incorporating 10 acidifying materials into absorbent products by coating, spraying, impregnating and the like, to impart to such products acidifying properties.

U.S. 4,431,427 to Lefren et al, discloses a tampon having incorporated therein one or more organic acids in combination with at least one of oligomer and polymer derivatives of the acids. The acids may be citric, glycolic, malic, tartaric 15 or lactic acids. The tampon is intended for maintaining a pH of about 4.5 to 2.5 in the fluids absorbed by the tampon during use, thereby inhibiting the growth of pathogenic bacteria in the tampon.

U.S. 4,661,101 to Sustmann discloses a catamenial tampon comprising a microbistatic fibrous absorbant core and an outer covering layer of a pH-regulating 20 fibrous, cellulose material. The cellulose fibers are modified by carboxymethyl groups which are converted into their free acid form by treatment with an acid.

WO 91/08726 discloses a disposable sanitary napkin comprising a water permeable topsheet, an absorbent core and a water impermeable backsheet. The topsheet and/or backsheet comprise absorbable, hydrolyzable and biodegradable 25 substances such as a lactic acid-based or glycolic acid-based polyester. This enhances the disposability of the napkin.

U.S. 6,020,453 to Larsson et al, discloses an absorbent article having a surface material, wherein the surface material includes a surface layer (being the outermost layer) which comprises a lactic acid-based polyester. The surface 30 material is capable of excreting lactic acid to the surrounding urogenital region of

- 3 -

menstruating women so as to establish a pH value of at most 4.0. The polyester has a molecular weight of at most 50,000 and the monomer/oligomer concentration is 5-30% by weight.

SUMMARY OF THE INVENTION

5 It is an object of the present invention to provide a novel formulation capable of reducing the pH in the menstruating vagina and/or in the tampon.

It is a further object of the invention to provide a novel delivery system for use with a feminine hygienic product, such as a tampon, to deliver an active agent to the female urogenital tract.

10 In a first aspect, the present invention provides a formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5 comprising:

- (a) 3-80% by weight of a solid organic acid polymer;
- (b) 92-15% by weight of a solid organic acid; and
- 15 (c) 5-30% of a wetting agent.

The formulation of the invention is believed to be effective in reducing the pH to below pH 5.5 in a vagina during menstruation and/or in a tampon inserted therein, and more preferably below pH 5.0, within a reasonable amount of time, such as within 0.5 hour. The components of the formulation are:

- 20 (a) an organic acid polymer which contributes to the long-term pH reduction;
- (b) a solid organic acid which contributes to the immediate pH reduction; and
- (c) a wetting agent for facilitating release of the organic acids.

25 The organic acid polymer of the formulation includes two or more monomers and is primarily non-acidic prior to hydrolysis. Examples of organic acid polymers include polylactic acid, polyglycolic acid and polymalic acid or copolymers of the above. A preferred organic acid polymer in the formulation of the invention is a polymer of lactic acid. Preferred polymers are L-lactide or

- 4 -

DL-lactide (LD), a racemic mixture of a cyclic dimer of lactic acid, and polylactic acid (PLA) in the general range of 200-2000 MW. The organic acid polymer comprises 3-80% of the formulation, preferably 60-80%, most preferably 70-80%.

Examples of solid organic acids are citric, malic, maleic, fumaric, succinic, 5 tartaric and oxalic acids. A preferred organic acid is citric acid. The organic acid comprises 92-15% of the formulation, and preferably 30-15%.

Examples of wetting agents which may be used in the formulation of the invention include glycerol, polyethylene glycol (PEG), polypropylene glycol (PPG) and surfactants with an HLB ranging from 10 to 18. Preferred wetting agents are 10 glycerol and PEG-8000. The wetting agent comprises 5-30% of the formulation, and preferably 5-10%.

The formulation may comprise additional substances such as stabilizers, perfuming agents, preservatives, anti-oxidants, chelating agents, adsorbents, analgesic agents, anti-inflammatory agents, etc.

15 In a second aspect, the invention provides a delivery system for releasing an active agent comprising:

- (a) a deposition comprising the active agent; and
- (b) a polymeric support on which the deposition is deposited.

15 The active agent may be any agent which performs a necessary function in the vagina such as an anti-bacterial, a pH-reducing or an deodorizing agent. 20 Preferably, the active agent is a pH reducing formulation according to the invention, except that in this aspect of the invention, the wetting agent is optional.

The deposited formulation may include any polymer capable of producing and facilitating a coherent deposition on the polymeric support material. Such 25 polymers include but are not limited to polyesters, olefins, cellulose and cellulose derivatives, PVA and PVP.

The polymeric support may be any polymeric material capable of serving as a support for the deposited material, and includes non-woven as well as woven materials. Examples of such support material include polypropylene, polyethylene,

- 5 -

cellulose and cellulose derivatives or any other polymer which can be processed as a fiber.

A preferred shape of the polymeric support is a rectangular strip, which preferably consists of one or more layers, for example, 2-16 layers. Other shapes 5 for the strip are also contemplated as part of the invention.

The delivery system of the invention is preferably used together with a catamenial tampon, as will be explained in more detail below.

Preferably, more than one delivery system will be placed in a tampon on different sides, so as to release the active agent in all directions.

10 Among the advantages of using the delivery system of the invention for releasing an active agent to the surrounding environment of the female urogenital tract is the contribution both to the economy of the manufacturing process of the tampon as well as to its reproducibility.

In a third aspect of the invention, there is provided A catamenial tampon 15 for insertion in a human vagina comprising:

- (a) an inner core comprising an absorbent material;
- (b) an outer layer comprising a liquid permeable material; and
- (c) a delivery system according to the invention.

Preferably, the delivery system incorporates the pH-reducing formulation of 20 the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

25 Fig. 1 shows the results of an *in vitro* study on the ability of various formulations to reduce the pH of 4ml of 0.1 N NaOH: a. 0.1 N NaOH; b. water + 0.1 N NaOH; c. water + 0.1 N NaOH + untreated tampon; d. water + (tampon prewetted with 0.1 N NaOH); e. water + 0.1 N NaOH + strip containing formulation; f. tampon with 2 strips containing formulation inserted bilaterally

- 6 -

lengthwise (T/L); **g.** tampon with 2 strips containing formulation inserted bilaterally widthwise (T/W);

Fig. 2 shows the results of an *in vitro* study on the ability of various substances to reduce the pH of 4ml of plasma: **a.** plasma; **b.** water + plasma; **c.** water + plasma + untreated tampon; **d.** water + (tampon prewetted with plasma); **e.** water + plasma + strip containing formulation; **f.** T/L; **g.** T/W; **h.** rolled-type tampon with 2 strips containing formulation inserted bilaterally lengthwise (T/D);

Fig. 3 shows the results of a SYNGINA study of tampons containing 3 strips with x1, x3 and x6 the original amount of formulated lactide: **a.** 4 ml of 0.1 N NaOH + 75ml water; **b.** Playtex™ tampon; **c.** T/L 3 strips containing together x6 the original amount of formulation (3x6); **d.** T/L (3x3); **e.** T/D (1x1); **f.** plasma (PL); **g.** T/L-PL (3x6); **h.** T/L-PL (3x3); **i.** strips without tampon (3x3);

Figs. 4a & 4b are graphs showing lactic acid release kinetics from welded or pressed (P) strips containing various formulations, by following pH decrease in plasma;

Fig. 5 shows the results of a SYNGINA study of tampons having citric acid-containing strips prepared by immersion; **a.** plasma; **b.** Lactide (LD) 100mg/glycerol (Glyc) 15%/Tween 80 (TW) 5% (I); **c.** LD 100mg/Glyc 15%/TW 5% (II); **d.** F-17; **e.** LD 100mg/Glyc 15%/TW 5% C-20mg; **f.** LD 50mg/Glyc 15%/TW 5% C-20mg; **g.** LD 25mg/Glyc 15% C-20mg; **h.** LD 25mg/Glyc 15% C-15mg; **i.** C-20mg/Glyc 15%;

Figs. 6a-6d show the results of a SYNGINA time-response study of tampons having citric acid-containing strips prepared by immersion; **a.** LD-L 100mg; **b.** LD 100mg/citric acid (CA) 20mg; **c.** LD 50mg/CA 20mg; **d.** LD 25mg/CA 20mg;

Fig. 7 shows the results of a SYNGINA time-response study of tampons having citric acid-containing strips incubated at 37°C.

Figs. 8a and 9a are perspective top views of a folded-type tampon in its flat form with two different embodiments of a delivery system in accordance with the invention;

- 7 -

Figs. 8b and 9b are perspective views of a folded-type tampon in its final folded and pressed form;

Figs. 8c and 9c are sectional views along lines 8c—8c and 9c—9c in Figs. 8b and 9b, respectively;

5 **Figs. 10a and 11a** are perspective top views of a rolled-type tampon in its flat form with two different embodiments of a delivery system in accordance with the invention;

Figs. 10b and 11b are perspective views of a rolled-type tampon in its final, rolled and pressed form; and

10 **Figs. 10c and 11c** are sectional views along lines 10c—10c and 11c—11c in Figs. 10b and 11b, respectively.

DETAILED DESCRIPTION OF THE INVENTION

I. FORMULATION

1. Initial studies

15 Lactide is readily hydrolyzed in water, even at room temperature. Hence, this material was tested for its pH neutralization ability.

An *in vitro* evaluation method was used, based on a procedure reported by Guthrie et al. (Industrial Engineering Chemistry, Vol. 44(9), pp 2187-88), according to which, the pH neutralization process of 4ml of a 0.1 N NaOH solution, closely 20 resembles that of a menstrual environment. The results of such a test, performed at room temperature using 75 mg of D,L-lactide to 4 ml of 0.1 N NaOH solution, are presented in **Table 1**.

- 8 -

TABLE 1: Reduction of the pH of 4 ml of 0.1N NaOH in the presence of 75 mg of lactide, as a function of time

Time	pH
0	12.45
5'	4.30
over night	3.50

5

The highly effective nature of this substance in reducing the pH is obvious. Nevertheless, it was evident that in order to obtain a progressive pH decrease to <5.5 within ~0.5 hour and to maintain the pH at that level for approximately 4-6 hours (hereinafter "*the prerequisite conditions*"), a suitable formulation had to be produced. Therefore, both lactide and polylactic acid (PLA) were combined, the first causing immediate pH reduction and the latter, being hydrolyzed at a slower rate, resulting in prolonged pH reduction.

A combination of lactide (80%), D,L PLA - (Resomer-R-203, Boehringer, MW=30000) (10%) and poly (ethylene glycol) (PEG) MW=8000 (10%), was used and loaded onto a polymeric support in the form of weighed, rectangular shaped pieces of non-woven (NW) tampon cloth (hereinafter: "*strips*") by evaporation from an acetone solution. PEG is a hydrosoluble compound which forms pores in the PLA matrix upon contact with water. The PEG molecules were added to the formulation in order to facilitate water penetration through the relatively hydrophobic PLA coating. The strips, mounted on microscope slides, were loaded with an approximate 50 mg net weight of lactide. The loaded strips were cut and tested in order to assess their pH neutralization efficacy. The tests were performed at room temperature and the results are presented in Table 2.

- 9 -

TABLE 2: Reduction of the pH of 4 ml of 0.1N NaOH in the presence of strips loaded with [LD 50mg/D,L-PLA 30,000 5 mg /PEG 8000 5 mg], as a function of time

Time	pH
0	12.48
15'	6.13
25'	5.36
35'	5.07
45'	4.90
55'	4.81
75'	4.69
17h	4.33

5

This release profile is much more controlled than that of pure lactide powder.

A similar experiment was carried out in order to assess the pH neutralization
10 efficacy of the samples in human plasma (Table 3).

- 10 -

TABLE 3: Reduction of the pH of 4 ml of plasma in the presence of NW loaded with [LD 50mg/D,L-PLA 30,000 5 mg /PEG 8000 5 mg], as a function of time

Time	pH
0	7.43
1'	6.60
5'	6.08
10'	5.80
15'	5.54
30'	5.04
60'	4.42
90'	4.12
120'	3.95

5

2. Method of strip preparation

2 ml of acetone solution containing a measured amount of the formulation were loaded on a strip (7.5x2.5 cm) by brushing and evaporation. The 10 formulation-containing strips were folded 3 times around the axial direction and 7.5 cm-long strips were prepared by pressing the folded material at 1 ton/cm² for 30 seconds. 8 or 16 layered strips were obtained by using a single or double non-woven PP/PE (NW), respectively.

For all formulations, the preparation of 7.5 cm-long strips of either 8 or 16 15 layered (NW) cloth, proved to be most suitable for the gradual release of lactic acid. The release of lactic acid from all the formulations, or from a single or double layered cloth not in the form of a strip, was rapid and immediately decreased the pH of the NaOH solution. Such a behavior was not considered appropriate, taking into consideration the prerequisite conditions defined above. Hence, all

- 11 -

formulations hereafter were designed and prepared as strips so as to attain the prerequisite conditions.

3. Formulation and *in vitro* studies

Based on the results described above, a series of formulation and processing related studies were performed. Accordingly, two main aspects were investigated:

- a. Formulation
- b. *In vitro* evaluation of formulated tampons

3a. Formulation studies:

Among the different formulations studied, those which proved the most efficacious, are listed below and compared:

- LD
- LD/PEG 0.1 (=10% of weight of LD used)
- 15 - LD/PLA 0.1
- LD/PLA 0.1/PEG 0.1

All formulations were loaded on the strips by evaporation from an acetone solution applied to the strip, as described above.

20 In order to quantitatively evaluate the amount of lactide present in each formulated strip, a titration method was developed, as a quality control procedure, as follows:

The formulated strip is incubated in 80 ml of a 0.01N NaOH solution at 37°C for 1hour, a period during which the lactide is hydrolyzed to lactic acid. The 25 solution is then titrated with 80 ml of a 0.01N HCl solution. Since 80 ml of 0.01N NaOH solution should be titrated by exactly 80 ml of 0.01N HCl solution, any difference in the titration amount (moles) of HCl, should account for an equivalent amount of lactic acid which was present in the sample.

- 12 -

3b. In vitro studies

Folded and pressed tampons (folded-type tampons – see Examples 1 and 2 below) were used in the majority of the following studies. The formulated strip-containing tampons (strips were introduced as described in Figs. 8 and 9 below) were tested *in vitro* with a 4 ml 0.1N NaOH solution or with plasma, both subsequently diluted in 75 ml of x2 distilled water, for measurement purposes. Either plasma or the 0.1N NaOH solution was dripped at a 0.1ml/min rate at 37°C and incubated for another 20 min (1 hour in total) before dilution and measurement. The results are summarized in Figures 1 and 2. It can be seen from these figures that the strip containing the formulation was the most effective in reducing the pH.

4. Improving lactic acid (LA) release from strip-containing tampon

The distinct difference in behavior between the formulated strip without a tampon and the strip-containing tampon is reflected in the resulting final pH values obtained in the *in vitro* studies described above.

The distinct decrease in LA release of the strip-containing tampon in comparison to that of the strip itself was related to the fact that not the whole length of the strip is wetted by the 4 ml volume of the added liquid, the strips being positioned lengthwise bilaterally underneath the outer layer of the tampon (see chapter on delivery system, below). According to the wetting profile obtained by using 4 ml of water containing methylene blue (not shown), only about a third of the strip's length was wetted.

According to these results, the total amount of formulated lactide was increased 3 and 6 fold per tampon in order to ensure the eventual release of the appropriate amount of lactic acid able to reduce the pH to the desired value in the tampon and/or in the surroundings. Increasing the amount of lactide was not expected to have an adverse effect, or to markedly reduce the pH below 3.

All *in vitro* studies hereafter were carried out in a device (named "SYNGINA"), recommended by the US FDA to simulate the lateral pressure acting on the tampon under natural conditions. Thus, the wetting profile inside the tampon

- 13 -

would resemble the natural conditions as closely as possible. Plasma, heated to 37°C, was added dropwise to the tampon inside the SYNGINA for a period of 20 min., after which the tampon was kept at 37°C for an additional 40 minutes (60 min. in total). The tampon was then immersed in 75 ml of x2 distilled water,
5 thoroughly squeezed for several seconds at which stage the pH was measured.

Figure 3 illustrates the final pH obtained in both plasma (PL) and the 0.1N NaOH solution, with x1, x3 and x6 the original amount of the formulation [LD 80%/D,L-PLA2000 10%/PEG8000 10%], equally divided between 3 strips per tampon. In the NaOH 0.1N solution, the x3 concentration lowers the pH significantly more than x1. Nevertheless, pH 7 is much higher than the desired pH 5.5. Also, no further decrease in pH is achieved by doubling the amount to x6. The x3 strip itself however, efficiently lowered the pH. This led to the conclusion that the amount of formulated substance is not the only parameter affecting LA release. All the formulations hereafter contained x3 amounts.
10

The second parameter which may affect LA release from the strip-containing tampon, stems from the possibility that the tampon material is more wettable than the strip itself, thus diminishing the accessibility of the liquid to the strip.
15

To overcome this effect, different formulations, of increased hydrophilicity were tested. Also, 8 and 4 layered laterally welded strips, positioned centrally in the tampon were used instead of the two 16 layered pressed strips used initially. The hydrophilisation process was achieved by either increasing the PEG content, or by replacing it with the more hydrophilic substance, glycerol.
20

First, the effect of both formulation and processing on the release kinetics of the strips themselves was tested. The graphs in Figs. 4A and 4B illustrate representative results.
25

In strips, all formulations seemed to perform similarly well, with a distinct difference between pressed and welded samples. In contrast to the expected effect, in most cases the pressed strips exhibited a more accelerated release pattern than
30 the welded ones. A reasonable explanation for this behavior is the possible

- 14 -

formation of embedded LD in polymeric matrix caused by the local strip PE melting process. This effect, however, was not observed in the most hydrophilic formulations.

5 **5. Effect of strip positioning:**

The most favorable strip positioning proved to be the use of a plurality of strips, preferably two strips and most preferably three strips positioned on opposite sides of the tampon, so that the strips are closer to the tampon surface at the end of the manufacturing process. Positioning the SYNGINA containing the tampon at
10 45° did not significantly effect the results.

6. Citric acid-containing formulations:

Most of the possible parameters influencing efficacy of pH adjustment were explored. At this stage, an *in vitro* pH value lower than 5.5 – 5.7 was very difficult
15 to achieve. It was concluded that the active ingredient itself, i.e. lactide, is probably the limiting factor in this case. Although, as described in the initial study section, lactide is the PLA of the lowest possible molecular weight, it is still hydrophobic and is dissolved in water (and thus released as lactic acid) only after hydrolysis. It was thus decided that an additional organic acid should be included in the
20 formulation. Citric acid (CA) proved to be the most suitable candidate, being both hydrophilic and crystalline as well as constituting a natural metabolite in the human body, as lactic acid.

Including CA in the formulation would, in parallel, contribute to:

- 25
 - shortening response induction time to an actual instant response; the lactide component contributing to a longer term response;
 - lowering formulation costs, by decreasing the necessary amount of lactide – CA being of a significantly lower price than lactide.

First, 4 ml of plasma were titrated with CA in order to assess the required amount of CA in the formulation. Even though the buffering effect of the plasma is
30 evident, only 22.8 mg of CA were necessary to lower the pH to 5. Accordingly, 20

- 15 -

mg of CA were used in formulations containing decreasing amounts of lactide in combination with glycerol with or without tween 80 (Fig. 5).

The optimal formulation among those tested, was the one containing 50 mg lactide, 20 mg CA, 7.5 mg glycerol and 2.5 mg Tween-80 (named C-2). PEG may
5 be used to replace Tween

In addition, a time response study was performed on four of the formulated tampons exhibited in Fig. 5. Again, C-2 proved to be the optimal formulation (Figs. 6a-d), initially lowering the pH to 4.56 within the first hour, and further decreasing it to 4.17 by the end of a four-hour incubation period.

10 Finally, a formulation, C-2B, similar to C-2 only without the Tween 80, was tested in the SYNGINA in a 37°C room by dripping different plasma volumes for different time periods, at 5 min intervals. The results are presented in Fig. 7. Although under these conditions the response appeared to be somewhat faster, a similar final pH value of about 4 was obtained. With plasma amounts lower than 4
15 ml, pH values were significantly lower, the extraction method used in these studies being unsuitable in this case. With 8 ml of plasma, an expected higher pH value of 4.8 was measured.

II. DELIVERY SYSTEM

20 The delivery system of the invention is composed of a polymeric support, such as a non-woven polymer, on which a deposition is deposited. The deposition comprises an active agent which may be released to the surrounding environment. Examples of such active agents include bactericidal agents, deodorizing agents, medically active substances and pH controlling agents. In a preferred embodiment,
25 the pH controlling agent is the formulation disclosed above. In one embodiment, the active agent is dissolved in a solvent which is applied to the support. The deposition is deposited by evaporation of the solvent

The polymeric support is placed near the surface of the tampon. Preferably, the delivery system is positioned between the inner absorbent core of the tampon
30 and its outer covering layer. The polymeric support may be in any geometrical

- 16 -

form or shape. Preferably, the support is in the form of rectangular strips of material, although other shapes are also possible. A plurality of these strips may be placed on different sides of the tampon in order to release the active agent in all directions. In the following discussion, several non-limiting examples are provided
5 of tampons prepared according to the invention.

Example 1

Tampons which undergo both radial and longitudinal expansion are generally manufactured for use with various types of applicator devices. The longitudinal expansion is generally more than 10% of its unexpanded length. This
10 type of tampon comprises an inner core of absorbent material, such as cellulose fibers and/or cotton fibers, enveloped by an outer layer of liquid permeable material such as a non-woven polymer, as for example polypropylene, polyethylene, polyester, cellulose, cellulose derivatives, or any combination of the above. This type of tampon is referred to in this specification as a "*folded-type*" tampon.

A folded-type tampon according to one embodiment of the invention is illustrated in Fig. 8a, in which can be seen a tampon 2 in its flat form comprising a body 4 and a withdrawal cord 6. The body 4 of the tampon comprises an outer layer 8 enveloping an inner absorbent core 10. The outer layer is held to the inner core in ways well known in the art, such as sewing or welding. The flat body has
15 an upper 12 and a lower 14 surface.

In this embodiment, a delivery system according to the invention in the form of three rectangular polymeric strips are positioned between the outer layer and the inner core, in parallel to the longitudinal axis of the body. One relatively wide strip
20 16 is on the upper surface 12 of the body (under the outer layer 8) and two narrow strips 18 are on the lower surface 14. The length of the strips may be approximately equal to the length of the flat body, and preferably equal to it. Preferably, the width of the wide strip is approximately twice the width of the narrow strips. Typical, non-limiting dimensions may be as follows: length and
25 width of flat tampon - 5-9.5 and 4-5 cm, respectively; widths of wide and narrow strips - 1.5-2.5 cm and 0.7-1.5 cm, respectively.
30

- 17 -

When the tampon is folded, it is compressed both lengthwise and widthwise to form the conventional tampon shape, as shown in Fig. 8b. The strips 18 are aligned near the outer surface of the body of the tampon. The tampon takes on a W-like shape in cross-section, as illustrated in Fig. 8c, in which can be seen the 5 inner core 10, the outer layer 8 and the wide 16 and narrow 18 strips below the outer layer. It may be seen from the figure that the edges of the wide strip 16 are folded within the folds of the inner core 10, thereby releasing the active agent absorbed therein to within the tampon as well as to the surrounding environment.

10 **Example 2**

In another embodiment, illustrated in Fig. 9a, three strips are positioned at spaced intervals between the outer layer 22 and the inner core 24 of the flat tampon 28, perpendicularly to the longitudinal axis of the flat body 26 of the tampon. In this embodiment, the strips are wound around the width of the body 26 and then 15 excised at the lateral edges 30 of the body so that there are 3 strips 20 on the upper surface 32 of the body and 3 corresponding strips 34 on the underside of the body. The length of each of the strips is equal to the width of the flat tampon. Preferably, the strips are positioned closer to the front end 36 of the tampon, opposite the withdrawal cord 38, since this is the end with which the menstrual fluid first comes 20 into contact.

The folded tampon 40 is illustrated in Fig. 9b, in which can be seen the annular strips 20. Fig. 9c shows how the strips 20,34 appear near the outer surface of the tampon between the outer layer 22 and the inner core 24, as well as within the folds of the inner core.

25 **Example 3**

A typical tampon which undergoes primarily radial expansion (<10% longitudinal expansion, if at all) is referred to in this specification as a "*rolled-type*" tampon and is shown in Figs. 10a-10c. As in the folded-type tampon described above, it comprises an inner core of absorbent material, as in Example 1, enveloped 30 by an outer layer of liquid permeable material, as in Example 1. The rolled-type

- 18 -

tampon differs from the folded-type tampon, *inter alia*, in their dimensions as well as in the manner of forming of the tampon. These differences affect the placement of the strips.

As shown in Fig. 10a, the flat tampon 48 comprises an absorbent layer 50 on 5 which is placed an outer layer 52. The absorbent layer 50 is in the form of an extended rectangular ribbon. The material of the outer layer 52 is generally heat sealed to the upper side of the absorbent layer near one of its ends 54, an extension 56 of the outer layer partly extending beyond the end 54 of the absorbent layer. The length of the extension 56 is substantially equivalent to the circumference of the 10 tampon in its final, folded form.

According to one embodiment of the invention, three parallel spaced rectangular polymeric strips 58 are positioned equidistantly from each other, perpendicular to the longitudinal axis of the outer layer, and between the absorbent layer 50 and the outer layer 52. The ends of the strips are distanced from the 15 longitudinal edges of the outer layer, and the strip 60 closest the end 54 of the absorbent layer is inwardly displaced from that end. The distance from the strip 62 farthest from the end 54 of the absorbent layer to that end is approximately equal to the circumference of the tampon in its folded form.

Typical, non-limiting dimensions of the various tampon components are 20 given below for exemplary purposes only: length, width and thickness of absorbent layer – 20-30 cm, 4-6 cm and 0.4-1.0 cm, respectively; length and width of outer layer – 5-15 cm and 4-4.5 cm; circumference of tampon – 3-4.5 cm; length of strips – 3.5-5.5 cm.

Fig. 10b shows the tampon 64 in its folded form comprising the body 66 and 25 withdrawal cord 68. During the forming process, the absorbent layer of the flat tampon (Fig. 10a) is rolled up onto itself along its longitudinal axis towards the end on which the strips and outer layer are placed, and the extension 56 of the outer layer is heat welded to the opposite end of the outer layer, thus enveloping the absorbent layer which now forms the core of the tampon. Two of the three strips 58 30 may be seen in Fig. 10b through the outer layer, with the third strip out of sight

- 19 -

behind the body of the tampon. Fig. 10c shows the three components of the tampon according to the invention: the rolled up inner absorbent core 50, the outer layer 52 and the strips 58.

Example 4

5 In this embodiment, illustrated in Figs. 11a-11c, the strips are placed parallel to the longitudinal axis of the outer layer rather than perpendicular thereto. Thus, Fig. 11a illustrates the absorbent layer 60 and outer layer 62 of the flat tampon 63 as in the previous example. Three parallel equidistant strips 64 are placed between the two layers in parallel to the longitudinal axis of the outer layer. The length of
10 each strip is equal to the circumference of the tampon in its final form. Preferably, the strips are placed proximate to the anterior end of the folded tampon.

Figs. 11b and 11c show the tampon 66 in its folded form comprising the inner core 60, the outer layer 62 and the strips 64.

- 20 -

CLAIMS:

1. A formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5 comprising:
 - (a) 3-80% by weight of a solid organic acid polymer;
 - 5 (b) 92-15% by weight of a solid organic acid; and
 - (c) 5-30% of a wetting agent.
2. A formulation according to Claim 1 wherein said organic acid polymer is selected from the group consisting of polylactic acid, polyglycolic acid and polymalic acid.
- 10 3. A formulation according to Claim 2 wherein said organic acid polymer is a lactide.
4. A formulation according to Claim 3 wherein said organic acid polymer is DL-lactide or L-lactide.
5. A formulation according to Claim 1 wherein said solid organic acid is selected from the group consisting of citric, malic, maleic, fumaric, succinic, tartaric and oxalic acids.
- 15 6. A formulation according to Claim 1 wherein said wetting agent is selected from the group consisting of glycerol, polyethylene glycol (PEG), polypropylene glycol (PPG) and surfactants with an HLB ranging from 10 to 18.
- 20 7. A delivery system for releasing an active agent comprising:
 - (a) a deposition comprising said active agent; and
 - (b) a polymeric support on which said deposition is deposited.
8. A delivery system according to Claim 7 wherein said active agent is a pH-reducing formulation.
- 25 9. A delivery system according to Claim 8 wherein said pH-reducing formulation comprises:
 - (a) 3-80% by weight of a solid organic acid polymer;
 - (b) 92-15% by weight of an organic acid; and
 - (c) optionally 5-30% of a wetting agent.

- 21 -

10. A delivery system according to Claim 7 wherein the components of said deposition are dissolved in a solvent and the deposition is deposited by evaporation of said solvent.
11. A delivery system according to Claim 7 wherein said polymeric support 5 comprises a non woven polymer.
12. A delivery system according to Claim 7 wherein said polymeric support is in the form of a strip.
13. A delivery system according to Claim 12 wherein said strip consists of a plurality of layers.
- 10 14. A delivery system according to Claim 13 wherein said strip consists of 2-16 layers.
15. A catamenial tampon for insertion in a human vagina comprising:
 - (a) an inner core comprising an absorbent material;
 - (b) an outer layer comprising a liquid permeable material; and
 - 15 (c) a delivery system according to any of Claims 7-14.
16. A tampon according to Claim 15 wherein said delivery system is positioned between said inner core and said outer layer.
17. A tampon according to Claim 15 wherein said delivery system comprises a plurality of strips of the polymeric support.
- 20 18. A tampon according to Claim 17 comprising 3 strips.
19. A tampon according to any of the previous claims wherein said delivery system incorporates a formulation effective in reducing the pH in the vagina of a menstruating woman or in a tampon inserted therein comprising:
 - (a) 3-80% by weight of a solid organic acid polymer;
 - 25 (b) 92-15% by weight of an organic acid; and
 - (c) optionally 5-30% of a wetting agent.
20. A tampon according to Claim 19 wherein said organic acid polymer is selected from the group consisting of polylactic acid, polyglycolic acid and polymalic acid.

- 22 -

21. A tampon according to Claim 20 wherein said organic acid polymer is a lactide.
22. A tampon according to Claim 21 wherein said organic acid polymer is DL-lactide or L-lactide.
- 5 23. A tampon according to Claim 19 wherein said solid organic acid is selected from the group consisting of citric, malic, maleic, fumaric, succinic, tartaric and oxalic acids.
24. A tampon according to Claim 19 wherein said wetting agent is selected from the group consisting of glycerol, polyethylene glycol (PEG), polypropylene 10 glycol (PPG) and surfactants with an HLB ranging from 10 to 18.

1/13




Fig. 1

2/13

IV-PLASMA




Fig. 2

3/13




Fig. 3

4/13




Fig. 4a

5/13




Fig. 4b

6/13




Fig. 5

7/13




Fig. 6a




Fig. 6b

8/13




Fig. 6c




Fig. 6d

9/13




Fig. 7

10/13




FIG. 8a




FIG. 8b




FIG. 8c

11/13




FIG. 9a




FIG. 9b



FIG. 9c

12/13




FIG. 10a




FIG. 10b




FIG. 10c


13/13

FIG. 11a




FIG. 11b




FIG. 11c

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IL 01/00419

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61L15/46 A61L15/20 A61L15/26 A61L15/42 A61L15/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61L A61F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 45976 A (PROCTER & GAMBLE) 16 September 1999 (1999-09-16)	1,5-19, 23,24
Y	page 5, last paragraph page 14, line 16 -page 16, line 13 page 23, line 1 - line 25 claims	1-24
Y	US 4 431 427 A (LEFREN KARL E ET AL) 14 February 1984 (1984-02-14) cited in the application column 2, line 21 - line 32 claims	1-24
A	US 4 685 909 A (BERG RONALD W ET AL) 11 August 1987 (1987-08-11) claims	1,5, 7-19,23
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

14 August 2001

Date of mailing of the international search report

24/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Thornton, S

INTERNATIONAL SEARCH REPORT

		International Application No PCT/IL 01/00419
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	DATABASE WPI Section Ch, Week 200007 Derwent Publications Ltd., London, GB; Class A23, AN 2000-075767 XP002174912 & JP 11 323113 A (SHIMADZU CORP), 26 November 1999 (1999-11-26) abstract	1-24

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IL 01/00419

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9945976	A	16-09-1999	AU 3082099 A	27-09-1999	
			EP 1061964 A	27-12-2000	
US 4431427	A	14-02-1984	DE 3236768 A	21-04-1983	
			FR 2513875 A	08-04-1983	
			GB 2107192 A,B	27-04-1983	
			JP 58075548 A	07-05-1983	
US 4685909	A	11-08-1987	AT 81292 T	15-10-1992	
			AU 580411 B	12-01-1989	
			AU 5741586 A	20-11-1986	
			CA 1255887 A	20-06-1989	
			DE 3686903 A	12-11-1992	
			DE 3686903 T	04-03-1993	
			DK 226186 A	16-11-1986	
			EG 17685 A	30-08-1990	
			EP 0202127 A	20-11-1986	
			ES 294160 U	01-05-1988	
			FI 862008 A,B,	16-11-1986	
			GB 2175210 A,B	26-11-1986	
			GR 861238 A	28-08-1986	
			HK 10492 A	31-01-1992	
			IE 58360 B	08-09-1993	
			JP 2608052 B	07-05-1997	
			JP 62028402 A	06-02-1987	
			KR 9401376 B	21-02-1994	
			MX 170519 B	30-08-1993	
			PH 26954 A	03-12-1992	
			PT 82571 A,B	01-06-1986	
			SG 102991 G	17-01-1992	
JP 11323113	A	26-11-1999	NONE		